top of page

Helus Pharma reports positive Phase III HLP003 results in major depressive disorder

Writer: nuaxia
nuaxia
1 hour ago
2 min read

Helus Pharma has reported positive Phase III results for investigational deuterated psilocin treatment HLP003 in major depressive disorder, with statistically significant improvements in depression scores through 12 weeks.


Helus Pharma announced on 16 November 2026 that its Phase III APPROACH study evaluating HLP003, a deuterated psilocin-based investigational medicine, as adjunctive treatment for major depressive disorder had met its primary and key secondary endpoints in a trial involving 222 participants.


At week six, the company reported a 7.6-point placebo-adjusted improvement in Montgomery–Åsberg Depression Rating Scale score with statistical significance at p<0.0001, alongside a 7.0-point placebo-adjusted difference at week 12 and treatment effects observed as early as day two; three treatment-related serious adverse events were reported, and the results remain company-reported topline findings rather than evidence of regulatory approval.

Field

Content

Article Type

Industry Updates

Company

Helus Pharma

Investigational Medicine

HLP003

Active Compound Description

Deuterated psilocin

Development Stage

Phase III

Clinical Trial

APPROACH

Announcement Date

16 November 2026

Therapeutic Area

Psychiatry

Indication

Major depressive disorder

Treatment Setting

Adjunctive treatment

Trial Participants

222

Primary Endpoint Status

Met

Key Secondary Endpoints Status

Met

Clinical Rating Scale

Montgomery–Åsberg Depression Rating Scale

Rating Scale Abbreviation

MADRS

Primary Reported Assessment

Week six

Week Six Placebo-Adjusted Difference

7.6 MADRS points

Week Six Statistical Significance

p<0.0001

Week Twelve Placebo-Adjusted Difference

7.0 MADRS points

Earliest Reported Treatment Effect

Day two

Treatment-Related Serious Adverse Events

Three

Evidence Status

Company-reported topline Phase III results

FDA Approval Granted

No

Full Peer-Reviewed Publication

Not established in supplied summary

Long-Term Safety Evidence

Further data remain important

What Happened

Helus Pharma reported positive pivotal-stage efficacy findings for adjunctive HLP003 in major depressive disorder.

Why It Matters

The results suggest a potentially important investigational treatment approach for patients with major depressive disorder.

Clinical Significance

The reported trial met its primary and key secondary endpoints and demonstrated statistically significant improvements in depression severity scores.

Safety Significance

Three treatment-related serious adverse events were reported, requiring consideration alongside efficacy findings.

Evidence Clarification

Topline company results are not equivalent to independent confirmation or regulatory approval.

Regulatory Clarification

HLP003 remains investigational.

Key Takeaway

Helus Pharma reported positive Phase III HLP003 results in major depressive disorder, with additional regulatory and safety evaluation still required.

What to Watch

Full clinical data, adverse-event characterisation, long-term follow-up, regulatory submissions and confirmatory evidence.

Primary Source

Helus Pharma

Primary Source URL

https://ir.helus.com/news-releases/news-release-details/helus-pharma-announces-positive-topline-results-phase-3-approach

Submitted Source

GlobeNewswire

Submitted Source URL

https://www.globenewswire.com/news-release/2026/11/16/3403358/0/en/helus-pharma-announces-positive-topline-results-from-phase-3-approach-study-evaluating-hlp003-as-adjunctive-treatment-in-major-depressive-disorder.html

Relevant Date

16 November 2026


Discover how nuaxia can support your next medical education initiative:

Comments

Rated 0 out of 5 stars.
No ratings yet

Add a rating
bottom of page